Kyverna's kyv-101 receives u.s. fda ind clearance for treatment of patients with treatment-refractory stiff-person syndrome in the kysa-8 phase 2 trial

This ind clearance expands the use of kyv-101 car t-cell therapy in a phase 2, open-label kysa-8 clinical trial targeting a devastating neuroimmunological autoimmune disease kyv-101 is a fully human anti-cd19 car t-cell therapy designed for use in patients with b cell-driven autoimmune diseases emeryville, calif. , june 20, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the clearance of its investigational new drug (ind) application by the u.s. food and drug administration (fda) for its autologous, fully human anti-cd19 chimeric antigen receptor (car) t-cell product candidate, kyv-101, to be used for the treatment of stiff-person syndrome (sps) in kyverna's trial, named kysa-8.
CAR Ratings Summary
CAR Quant Ranking